Skip to main content

Table 9 Homogeneity of estimates of protective efficacy of pooled studies

From: Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries

Studies pooled Treatment Cochran’s Q-test Between study variancea Higgins and Thompson statisticsb
Q Stat P value* H (95 % CI) I 2 (95 % CI)
030 and 045 Placebo      
Tafenoquine 200 mg weekly 0.26 0.61 0.00 1.00 (1.0, 1.7) 0.00 (0.0, 0.7)
030, 043 and 045 Placebo      
Tafenoquine 200 mg weekly 0.70 0.71 0.00 1.00 (1.0, 1.4) 0.00 (0.0, 0.5)
  1. * p value is from a Chi square test of homogeneity of PE s between studies with degree of freedom k − 1, where k is the number of studies
  2. aBetween-study variance is estimated using the random effect model of DerSimonian and Laird [13]
  3. b H and I 2 calculations are based on Higgins and Thomson [8] and 95 % confidence intervals are based on Biggerstaff and Tweedie